October 13, 2018

ASRT: Assertio Holdings, Inc. Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	59.48
Enterprise Value ($M)	47.71
Book Value ($M)	121.08
Book Value / Share	1.26
Price / Book	0.49
NCAV ($M)	38.90
NCAV / Share	0.41
Price / NCAV	1.53

Profitability (mra)
Return on Invested Capital (ROIC)	-0.13
Return on Assets (ROA)	-0.08
Return on Equity (ROE)	-0.16

Liquidity (mrq)
Quick Ratio	1.43
Current Ratio	1.77

Balance Sheet (mrq) ($M)
Current Assets	202.55
Assets	284.73
Liabilities	163.65
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	124.96
Operating Income	-14.22
Net Income	-21.58
Earnings Per Share Basic And Diluted	n/a
Earnings Per Share Diluted	n/a
Earnings Per Share Basic	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	26.41
Cash from Investing	-48.91
Cash from Financing	-0.35
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
11-14	13G/A	Armistice Capital, Llc	0.00	-100.00
11-14	13G/A	Nantahala Capital Management, LLC	9.39	17.44
11-12	13G/A	Vanguard Group Inc	4.68	0.00
07-08	13G/A	BlackRock, Inc.	1.50	-78.92

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2025-03-12	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-12	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-07	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-06	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2025-04-17	73,003	276,341	26.42
2025-04-16	39,840	225,071	17.70
2025-04-15	31,049	166,965	18.60
(click for more detail)

Similar Companies
APVO – Aptevo Therapeutics Inc.	ARTL – Artelo Biosciences, Inc.
ASNS – Actelis Networks, Inc.	ATHA – Athira Pharma, Inc.
ATNF – 180 Life Sciences Corp.

Financial data and stock pages provided by
Fintel.io

Related